× ×ª×× × ×ª×¨×פ×
××רש×
| ××× ×× ×× × ×ספ××
|
|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
L01EX
Other protein kinase inhibitors
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
פ××× - PER OS
|
| צ×רת ××× ××
|
קפס××× ×§×©×××, HARD CAPSULE
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
LENVIMA is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).LENVIMA is indicated in combination with everolimus for the treatment of adult patients with advanced clear cell renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.LENVIMA is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.Lenvima, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum containing therapy and who are not candidates for curative surgery or radiation.LENVIMA is indicated in combination with pembrolizumab for the first-line treatment of adult patients with advanced RCC.
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 21/01/2016
|
×××××ת ×ס×
-
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×ש×××× ×¢× Pembrolizumab ×××פ×× ×סר×× ×¨×× ×תק×× ×× ×××ר ××××× ×©××× pMMR (mismatch repair proficient), ש××××ª× ×תק××× ××××× ×× ×××ר ×§× ××פ×× ××× ×× ××תר ש××× ××××תרפ×× ×××ססת פ×××× ×× ×××× ××× × ×××¢××ת ×× ×ת×× ×× ××§×¨× ×ת ×¢× ×¤××× ×¦××× ×§×ר×××××. ××××× ××××ª× ×ª××× ××××× ××××ת ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§×××××× ×× ×¨××¤× ××××× ×××× ×§×××××× ××××¤× ×××× ×§×××××× ××× ×§×××××ת.
|
17/03/2024 |
××× ×§×××××× |
|
סר×× ×¨×× ×תק××, pMMR (mismatch repair proficient) |
|
| סר×× ×××× ×תק×× ×× ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× Pembrolizumab ×ש×××× ×¢× Axitinib ×× ×ש×××× ×¢× Lenvatinib ×××××× ××ר×ת ס×××× poor ×× intermediate. ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors, ×שר ת××× ×××× ×ª× ××ש×× ××× ×××× ×¢× ×ª×ש×ר ×××שפ×ת ××¢××× ××ר×××× ×§×× ××. |
03/02/2022 |
××× ×§×××××× |
|
RCC, Renal cell carcinoma |
|
| סר×× ×פ××צ××××¨× ×תק×× ×× ×× × ×ª×× ×××××× ×©××¨× ×§×××× ××פ×× ×¡×ס××× ××××ת×. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×תר××¤× ××ת ×××× ××תר×פ×ת ××פ×ר××ת ×××× â Lenvatinib, Sorafenib |
16/01/2019 |
××× ×§×××××× |
|
Hepatocellular carcinoma, HCC |
|
| סר×× ×××× ×תק×× ×× ×ר×רת×, ×××ר ××©× ×××פ×× ×§××× |
11/01/2018 |
××× ×§×××××× |
|
Renal cell carcinoma, advanced |
|
| סר×× ×תק×× ×ק××× ×× ×ר××¨×ª× ×©× ××××ת ×תר×ס ×ס×× DTC (Differentiated (papillary / follicular / Hurthle cell) thyroid carcinoma) ×¢××× ×××× ×¨××××ק×××× |
21/01/2016 |
××× ×§×××××× |
|
DTC, Differentiated thyroid cancer |
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××:
- ××פ×× ×××××× ×××ר×× ×ס××××× ×סר×× ×תק×× ×ק××× ×× ×ר××¨×ª× ×©× ××××ת ×תר×ס ×ס×× DTCâ (papillary / follicular / Hurthle Differentiated cell thyroid carcinoma) ×¢××× ×××× ×¨××××ק××××.
××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§×××××× ×× ×¨××¤× ××××× ×××£ ×××× ×ר×× ×× ×¨××¤× ××××× ××× ××קר×× ××××××
- סר×× ×××× ×תק×× ×× ×ר×רת×, ×××ר ××©× ×××פ×× ×§×××.
××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§×××××× ×× ×¨××¤× ××××× ×××ר×××××× ××××¤× ×××ר×××××× ××× ×§×××××ת
- סר×× ×פ××צ××××¨× ×תק×× ×× ×× × ×ª×× ×××××× ×©××¨× ×§×××× ××פ×× ×¡×ס××× ××××ת×.
××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×תר××¤× ××ת ×××× ××תר×פ×ת ××פ×ר××ת ×××× - Lenvatinib, Sorafenib.
××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§××××××
- ×ש×××× ×¢× Pembrolizumab ×××פ×× ×סר×× ×¨×× ×תק×× ×× ×××ר ××××× ×©××× pMMR (proficient mismatch repair), ש××××ª× ×תק××× ××××× ×× ×××ר ×§× ××פ×× ××× ×× ××תר ש××× ××××תרפ×× ×××ססת פ×××× ×× ×××× ××× × ×××¢××ת ×× ×ת×× ×× ××§×¨× ×ת ×¢× ×¤××× ×¦××× ×§×ר×××××.
××××× ××××ª× ×ª××× ××××× ××××ת ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors
- ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§×××××× ×× ×¨××¤× ××××× ×××× ×§×××××× ××××¤× ×××× ×§×××××× ××× ×§×××××ת.
|
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
ת××× ×ª ×ר×××
ת×ר×× ×¢××××: 12/02/24
EISAI
×× ××××× - Lenvima
true
השינוי האחרון נעשה בֹ־18 ביולי 2025 ב־05:08
